Lung Cancer Non-Small Cell Cancer (NSCLC) Not Yet Recruiting Phase 2 Trials for Pemetrexed (DB00642)

Also known as: Non - Small Cell Lung Cancer NSCLC / Carcinoma, Non-Small-Cell Lung / Non-Small-Cell Lung Carcinoma (NSCLC) / Non-Small-Cell Lung Carcinoma / Nonsmall Cell Lung Cancer / Lung Cancer(NSCLC) / Non-Small Cell Lung Cancer / Non-Small-Cell Lung Cancer (NSCLC) / NSCLC (Non-Small Cell Lung Cancer) / Non Small Cell Lung Cancer (NSCLC) / Lung Cancer (Non-Small Cell) / NSCLC, Non Small Cell Lung Cancer / Non-small Cell Lung Cancers / Lung Cancer, Nonsmall Cell / Non-Small Cell Lung Carcinoma / Lung Cancer Non-Small Cell / Non-Small-Cell Lung Cancer / Non-Small Cell Lung Cancer (NSCLC) / Non Small Cell Lung Cancer / Non-Small Cell Lung Carcinoma (NSCLC) / Carcinoma, Non-Small Cell Lung / Lung Cancer, Non-Small Cell / Non Small-cell Lung Cancer / NSCLC Non-small Cell Lung Cancer / NSCLC / Non Small Cells Lung Cancer / Non-Small Cell Lung Cancer(NSCLC) / Non- Small Cell Lung Cancer / Lung Cancer - Non Small Cell / Lung Cancer (NSCLC) / Non Small Cell Lung Cancer NSCLC / Non-Small-Cell-Lung Cancer (NSCLC) / Non-Small-Cell-Lung Cancer / Non-small cell lung cancer (disorder) / Non-small cell lung cancer NOS

IndicationStatusPhase
DBCOND0046916 (Lung Cancer Non-Small Cell Cancer (NSCLC))Not Yet Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04265534A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLCTreatment
NCT03758677Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M MutationTreatment
NCT03770299An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual DiseaseTreatment
NCT02906150Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild TypeTreatment
NCT02930954Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation AbundanceTreatment
NCT02940990SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver MutationsTreatment
NCT04253964Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/ImmunotherapyTreatment
NCT03002844EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion PolymorphismTreatment
NCT02531854A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction ChemotherapyTreatment